Can alterations in MiR-21, MiR-1, and MiR-224 expression predict personalized medicine chemotherapy in non-small cell lung cancer?

Abstract Purpose Lung cancer is a significant global cancer death, necessitating urgent efforts to identify and develop biomarkers for detection and treatment. Cisplatin has been approved for the treatment of lung cancer, but the therapeutic efficacies are usually retarded by intrinsic and acquired resistance. Thus, an urgent need is crucial to use strategies to predict therapeutic responses. In previous studies, microRNAs were used only to predict drug resistance. However, in this study, we aimed to understand the roles of microRNAs (miR-21, miR-1, and miR-224) in personalized medicine chemotherapy by eliminating some factors, such as EGFR and PD_1, to specify the results. Methods FFPE samples were obtained from 30 metastatic NSCLC patients. Only negative molecular pd-1, pdl-1, and EGFR patient samples were collected to improve the sensitivity of the test. People were divided into two resistant and sensitive groups based on their response to cisplatin treatment. MiRNAs were extracted, and the expression level of miRNAs was quantified by qRT-PCR and normalized to the level of U6 small RNA. Statistical analyses were performed to compare miRNA levels between groups. Results The expression level of miR-21(P = 0.048) and miR-224 (P = 0.017) was notably higher in chemoresistance patients (P < 0.05), while the expression level of miR-1 (P = 0.035) was substantially higher in chemosensitive patients (P < 0.05). Conclusion This study was carried out with the final aim of paying attention to personalized medicine and showed that miR-21, miR-1, and miR-224 can act as potential biomarkers for personalized medicine in NSCLC.